FibroBiologics, Inc. (FBLG) Stock Forecast
FBLG analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.00 / 5 from 2 analysts
- Price target
- $12.50 average of analyst targets
- Upside to target
- +1,187.3% from the latest close
- Next earnings
- October 30, 2026 EPS estimate $-0.63
- 52-week range
- $0.63 – $8.73
FBLG analyst ratings
2 analystsNumber of analysts at each rating.
FBLG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FBLG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.63 | −$0.63 | −$0.63 | −$2.60 | +75.8% | 1 |
| Current fiscal year (FY2026) | −$3.00 | −$3.00 | −$3.00 | −$8.40 | +64.3% | 1 |
| Next fiscal year (FY2027) | −$3.25 | −$3.25 | −$3.25 | −$3.00 | −8.3% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FBLG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (FY2027) | $0 | $0 | $0 | 0.0% | 3 |
FBLG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FBLG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.77 | −$0.94 | −$0.94 | −$0.94 | −$0.63 | −18.2% | 1 up · 0 down |
| Current fiscal year (FY2026) | −$3.71 | −$4.01 | −$4.01 | −$4.01 | −$3.00 | −19.0% | 1 up · 0 down |
| Next fiscal year (FY2027) | −$3.85 | −$4.49 | −$4.49 | −$4.49 | −$3.25 | −15.5% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FBLG earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; FBLG beat in 7 of 9.
What analysts expect from FBLG
2 analysts cover FibroBiologics; their consensus rating is buy (4.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.50, 1,187.3% above the latest close of $0.97. Analysts expect earnings of −$3.00 per share for FY2026, +64.3% from a year earlier. For FY2027 the average estimate is −$3.25 per share. FibroBiologics beat the EPS estimate in 7 of the last 9 quarters.
Related: FBLG income statement, FBLG key metrics, FBLG chart. See the FBLG stock overview for the latest quote and news.
FBLG forecast FAQ
What is FibroBiologics's price target?
The average analyst price target for FibroBiologics is $12.50, 1,187.3% above the latest close of $0.97.
Is FibroBiologics a buy, hold or sell?
Of 2 analysts covering FibroBiologics, 1 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is FibroBiologics's EPS forecast?
Analysts forecast −$3.00 per share for FY2026 (range −$3.00 to −$3.00); for FY2027 the estimate is −$3.25.
When does FibroBiologics report earnings?
FibroBiologics is expected to report results for the quarter ending September 30, 2026 on October 30, 2026; the EPS estimate is $-0.63.
Does FibroBiologics usually beat earnings estimates?
FibroBiologics reported EPS at or above the analyst estimate in 7 of the last 9 quarters.